| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Surgical Wound Infection | 16 | 2023 | 273 | 3.410 |
Why?
|
| Elective Surgical Procedures | 7 | 2020 | 171 | 1.860 |
Why?
|
| Surgical Mesh | 10 | 2013 | 72 | 1.730 |
Why?
|
| Cross Infection | 6 | 2015 | 344 | 1.710 |
Why?
|
| Hernia, Ventral | 8 | 2013 | 44 | 1.620 |
Why?
|
| Herniorrhaphy | 5 | 2013 | 83 | 1.580 |
Why?
|
| Postoperative Complications | 16 | 2025 | 3172 | 1.400 |
Why?
|
| Laparoscopy | 14 | 2018 | 520 | 1.290 |
Why?
|
| General Surgery | 10 | 2011 | 220 | 1.270 |
Why?
|
| Hernia, Inguinal | 7 | 2009 | 45 | 1.140 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 5 | 2015 | 230 | 1.130 |
Why?
|
| Preoperative Care | 7 | 2020 | 373 | 1.070 |
Why?
|
| Staphylococcal Infections | 5 | 2015 | 573 | 1.020 |
Why?
|
| Catheter-Related Infections | 2 | 2020 | 139 | 0.970 |
Why?
|
| Emergencies | 3 | 2018 | 187 | 0.930 |
Why?
|
| Collagen | 4 | 2009 | 330 | 0.860 |
Why?
|
| Guideline Adherence | 2 | 2020 | 400 | 0.860 |
Why?
|
| Surgical Procedures, Operative | 5 | 2017 | 193 | 0.860 |
Why?
|
| Intensive Care Units | 3 | 2017 | 541 | 0.830 |
Why?
|
| Crush Injuries | 1 | 2023 | 5 | 0.830 |
Why?
|
| Operating Rooms | 3 | 2017 | 75 | 0.820 |
Why?
|
| Hernia, Abdominal | 3 | 2018 | 19 | 0.800 |
Why?
|
| Abdominal Wall | 3 | 2009 | 36 | 0.800 |
Why?
|
| Rectal Neoplasms | 4 | 2018 | 81 | 0.790 |
Why?
|
| Digestive System Surgical Procedures | 5 | 2018 | 89 | 0.790 |
Why?
|
| Anti-Bacterial Agents | 8 | 2018 | 2592 | 0.780 |
Why?
|
| Pressure Ulcer | 1 | 2023 | 79 | 0.780 |
Why?
|
| Colonic Neoplasms | 6 | 2018 | 271 | 0.770 |
Why?
|
| Laparotomy | 3 | 2011 | 143 | 0.730 |
Why?
|
| Staphylococcus aureus | 3 | 2015 | 480 | 0.720 |
Why?
|
| Retrospective Studies | 45 | 2025 | 17591 | 0.720 |
Why?
|
| Skin, Artificial | 3 | 2009 | 8 | 0.700 |
Why?
|
| Middle Aged | 54 | 2025 | 29430 | 0.680 |
Why?
|
| Antibiotic Prophylaxis | 3 | 2018 | 129 | 0.680 |
Why?
|
| Safety Management | 2 | 2020 | 121 | 0.670 |
Why?
|
| Urinary Catheters | 1 | 2020 | 26 | 0.660 |
Why?
|
| Risk Management | 1 | 2020 | 69 | 0.650 |
Why?
|
| Health Facilities | 1 | 2020 | 66 | 0.640 |
Why?
|
| Biocompatible Materials | 3 | 2009 | 127 | 0.620 |
Why?
|
| Catheters, Indwelling | 1 | 2020 | 159 | 0.610 |
Why?
|
| Quality of Health Care | 2 | 2020 | 424 | 0.610 |
Why?
|
| Hospital Mortality | 7 | 2020 | 1100 | 0.610 |
Why?
|
| Internship and Residency | 7 | 2010 | 1255 | 0.610 |
Why?
|
| Veterans | 8 | 2022 | 1788 | 0.600 |
Why?
|
| Length of Stay | 14 | 2025 | 1392 | 0.600 |
Why?
|
| Health Care Costs | 3 | 2017 | 409 | 0.590 |
Why?
|
| Medical Errors | 1 | 2020 | 162 | 0.590 |
Why?
|
| Humans | 97 | 2025 | 134225 | 0.590 |
Why?
|
| Data Collection | 1 | 2020 | 399 | 0.580 |
Why?
|
| Recurrence | 13 | 2013 | 1470 | 0.560 |
Why?
|
| Perioperative Care | 2 | 2012 | 212 | 0.560 |
Why?
|
| Aged | 41 | 2025 | 21822 | 0.550 |
Why?
|
| Nurse Specialists | 1 | 2017 | 1 | 0.540 |
Why?
|
| Follow-Up Studies | 16 | 2015 | 5466 | 0.530 |
Why?
|
| Male | 63 | 2025 | 66215 | 0.530 |
Why?
|
| Liver Cirrhosis | 3 | 2018 | 948 | 0.530 |
Why?
|
| Advanced Practice Nursing | 1 | 2017 | 8 | 0.530 |
Why?
|
| Medical Futility | 1 | 2017 | 39 | 0.530 |
Why?
|
| Intraoperative Complications | 1 | 2018 | 164 | 0.530 |
Why?
|
| Soft Tissue Infections | 3 | 2011 | 91 | 0.520 |
Why?
|
| Sodium | 1 | 2018 | 308 | 0.520 |
Why?
|
| Incidence | 11 | 2020 | 3424 | 0.520 |
Why?
|
| Nurse's Role | 1 | 2017 | 41 | 0.520 |
Why?
|
| Patient Readmission | 3 | 2017 | 430 | 0.520 |
Why?
|
| Pneumonia, Ventilator-Associated | 2 | 2014 | 44 | 0.510 |
Why?
|
| Orthopedic Procedures | 2 | 2015 | 76 | 0.510 |
Why?
|
| United States Department of Veterans Affairs | 5 | 2017 | 715 | 0.500 |
Why?
|
| Leadership | 3 | 2010 | 243 | 0.500 |
Why?
|
| Hospitals, Veterans | 10 | 2017 | 365 | 0.500 |
Why?
|
| Texas | 14 | 2020 | 3719 | 0.490 |
Why?
|
| Urinary Tract Infections | 1 | 2020 | 314 | 0.490 |
Why?
|
| Health Resources | 1 | 2017 | 127 | 0.490 |
Why?
|
| Decontamination | 1 | 2015 | 13 | 0.470 |
Why?
|
| Methicillin Resistance | 2 | 2007 | 118 | 0.460 |
Why?
|
| Quality Improvement | 2 | 2020 | 701 | 0.460 |
Why?
|
| Mandatory Reporting | 1 | 2014 | 18 | 0.450 |
Why?
|
| Carrier State | 1 | 2015 | 78 | 0.450 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 298 | 0.450 |
Why?
|
| Female | 54 | 2025 | 72054 | 0.440 |
Why?
|
| Oxazolidinones | 1 | 2014 | 34 | 0.430 |
Why?
|
| Clinical Protocols | 1 | 2015 | 245 | 0.430 |
Why?
|
| Acetamides | 1 | 2014 | 51 | 0.420 |
Why?
|
| Bacteremia | 2 | 2015 | 429 | 0.420 |
Why?
|
| Treatment Outcome | 24 | 2018 | 13105 | 0.420 |
Why?
|
| Prostheses and Implants | 1 | 2015 | 153 | 0.420 |
Why?
|
| Ceftazidime | 1 | 2014 | 50 | 0.420 |
Why?
|
| Prosthesis Implantation | 1 | 2015 | 152 | 0.410 |
Why?
|
| Cephalosporins | 1 | 2014 | 143 | 0.410 |
Why?
|
| Pneumonia, Bacterial | 1 | 2014 | 81 | 0.410 |
Why?
|
| Colostomy | 1 | 2013 | 28 | 0.400 |
Why?
|
| Liver Failure, Acute | 2 | 2005 | 96 | 0.380 |
Why?
|
| Abdominal Cavity | 1 | 2011 | 8 | 0.370 |
Why?
|
| Fasciotomy | 1 | 2011 | 26 | 0.370 |
Why?
|
| Vas Deferens | 1 | 2011 | 24 | 0.360 |
Why?
|
| Vasectomy | 1 | 2011 | 18 | 0.360 |
Why?
|
| Hepatitis C, Chronic | 1 | 2015 | 373 | 0.360 |
Why?
|
| Hernia, Umbilical | 3 | 2008 | 43 | 0.350 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 657 | 0.350 |
Why?
|
| Abdomen, Acute | 1 | 2010 | 14 | 0.350 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 772 | 0.340 |
Why?
|
| Perioperative Period | 1 | 2010 | 54 | 0.340 |
Why?
|
| Minimally Invasive Surgical Procedures | 3 | 2018 | 194 | 0.330 |
Why?
|
| Polypropylenes | 2 | 2007 | 16 | 0.330 |
Why?
|
| Infection Control | 3 | 2018 | 161 | 0.330 |
Why?
|
| Electric Countershock | 1 | 2010 | 74 | 0.330 |
Why?
|
| Pain, Postoperative | 2 | 2013 | 277 | 0.330 |
Why?
|
| Personality Inventory | 1 | 2010 | 176 | 0.330 |
Why?
|
| Digestive System Diseases | 1 | 2009 | 19 | 0.320 |
Why?
|
| Colectomy | 6 | 2010 | 84 | 0.320 |
Why?
|
| Multivariate Analysis | 6 | 2015 | 1493 | 0.310 |
Why?
|
| Patient Satisfaction | 1 | 2013 | 489 | 0.310 |
Why?
|
| Urogenital Abnormalities | 1 | 2011 | 168 | 0.310 |
Why?
|
| Mental Disorders | 1 | 2016 | 890 | 0.300 |
Why?
|
| Survival Rate | 6 | 2018 | 2214 | 0.300 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2010 | 228 | 0.300 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 1166 | 0.300 |
Why?
|
| Fluid Therapy | 2 | 2025 | 149 | 0.290 |
Why?
|
| Abdomen | 1 | 2009 | 136 | 0.290 |
Why?
|
| Logistic Models | 9 | 2015 | 1909 | 0.280 |
Why?
|
| Risk Assessment | 8 | 2020 | 3754 | 0.280 |
Why?
|
| Educational Measurement | 3 | 2010 | 333 | 0.280 |
Why?
|
| Adult | 22 | 2018 | 31962 | 0.280 |
Why?
|
| Practice Guidelines as Topic | 3 | 2012 | 1344 | 0.280 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2007 | 40 | 0.280 |
Why?
|
| United States | 16 | 2018 | 11798 | 0.270 |
Why?
|
| Interpersonal Relations | 2 | 2008 | 229 | 0.270 |
Why?
|
| Fascia | 2 | 2018 | 16 | 0.270 |
Why?
|
| Professional Competence | 1 | 2007 | 98 | 0.260 |
Why?
|
| Analysis of Variance | 6 | 2016 | 1044 | 0.260 |
Why?
|
| Clinical Competence | 4 | 2017 | 1068 | 0.260 |
Why?
|
| Comorbidity | 4 | 2016 | 1628 | 0.260 |
Why?
|
| Gangrene | 3 | 2004 | 27 | 0.250 |
Why?
|
| Risk Factors | 16 | 2018 | 11196 | 0.250 |
Why?
|
| Sepsis | 3 | 2009 | 522 | 0.240 |
Why?
|
| Colorectal Neoplasms | 4 | 2015 | 652 | 0.240 |
Why?
|
| Hemodiafiltration | 2 | 2005 | 18 | 0.240 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2007 | 252 | 0.240 |
Why?
|
| Patient Care Team | 2 | 2011 | 577 | 0.240 |
Why?
|
| Inservice Training | 1 | 2005 | 56 | 0.240 |
Why?
|
| Cohort Studies | 8 | 2020 | 5225 | 0.240 |
Why?
|
| Postoperative Hemorrhage | 2 | 2019 | 84 | 0.240 |
Why?
|
| Inguinal Canal | 1 | 2004 | 13 | 0.230 |
Why?
|
| Anastomotic Leak | 2 | 2018 | 34 | 0.230 |
Why?
|
| Intraoperative Care | 1 | 2025 | 120 | 0.230 |
Why?
|
| Cholecystitis, Acute | 1 | 2004 | 17 | 0.230 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2018 | 87 | 0.220 |
Why?
|
| Heart Rate | 1 | 2007 | 601 | 0.220 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2025 | 106 | 0.220 |
Why?
|
| Interprofessional Relations | 1 | 2005 | 157 | 0.220 |
Why?
|
| Emergency Treatment | 1 | 2004 | 86 | 0.210 |
Why?
|
| Suture Techniques | 4 | 2012 | 188 | 0.210 |
Why?
|
| Cathartics | 2 | 2018 | 31 | 0.210 |
Why?
|
| Multiple Organ Failure | 2 | 2005 | 144 | 0.200 |
Why?
|
| Spider Bites | 1 | 2003 | 1 | 0.200 |
Why?
|
| Parathyroid Neoplasms | 1 | 2003 | 23 | 0.200 |
Why?
|
| Parathyroid Glands | 1 | 2003 | 29 | 0.200 |
Why?
|
| Hyperparathyroidism | 1 | 2003 | 26 | 0.200 |
Why?
|
| Atrial Fibrillation | 1 | 2010 | 702 | 0.200 |
Why?
|
| Lithium | 1 | 2003 | 71 | 0.200 |
Why?
|
| Communication | 1 | 2007 | 542 | 0.200 |
Why?
|
| Anus Neoplasms | 2 | 2018 | 42 | 0.200 |
Why?
|
| Time Factors | 6 | 2018 | 6595 | 0.200 |
Why?
|
| Pleurodesis | 1 | 2002 | 16 | 0.190 |
Why?
|
| Endosonography | 1 | 2002 | 81 | 0.190 |
Why?
|
| Serum Albumin | 2 | 2006 | 116 | 0.190 |
Why?
|
| Attitude of Health Personnel | 1 | 2008 | 722 | 0.190 |
Why?
|
| Biopsy, Needle | 1 | 2002 | 237 | 0.190 |
Why?
|
| Knowledge | 1 | 2002 | 51 | 0.190 |
Why?
|
| Doxycycline | 1 | 2002 | 121 | 0.180 |
Why?
|
| Surgical Wound Dehiscence | 2 | 2012 | 51 | 0.180 |
Why?
|
| APACHE | 3 | 2010 | 57 | 0.180 |
Why?
|
| Adenoma | 1 | 2003 | 147 | 0.180 |
Why?
|
| Shock | 1 | 2022 | 99 | 0.180 |
Why?
|
| Surveys and Questionnaires | 5 | 2010 | 4008 | 0.170 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 2013 | 92 | 0.170 |
Why?
|
| Antidepressive Agents | 1 | 2003 | 327 | 0.170 |
Why?
|
| Reoperation | 3 | 2013 | 853 | 0.160 |
Why?
|
| Digestive System Neoplasms | 2 | 2014 | 14 | 0.160 |
Why?
|
| Respiratory Insufficiency | 1 | 2002 | 240 | 0.160 |
Why?
|
| Chemoradiotherapy | 2 | 2018 | 127 | 0.160 |
Why?
|
| Hemostasis, Surgical | 1 | 2019 | 36 | 0.160 |
Why?
|
| Operative Time | 2 | 2018 | 189 | 0.160 |
Why?
|
| Nutrition Assessment | 1 | 2020 | 138 | 0.160 |
Why?
|
| Curriculum | 1 | 2004 | 768 | 0.150 |
Why?
|
| Critical Care | 3 | 2015 | 698 | 0.150 |
Why?
|
| Hemostatics | 1 | 2019 | 62 | 0.150 |
Why?
|
| Predictive Value of Tests | 3 | 2015 | 2319 | 0.150 |
Why?
|
| Anti-Infective Agents, Local | 2 | 2010 | 71 | 0.150 |
Why?
|
| Aged, 80 and over | 9 | 2014 | 7244 | 0.150 |
Why?
|
| Students, Medical | 2 | 2006 | 363 | 0.150 |
Why?
|
| Hepatocytes | 3 | 2005 | 245 | 0.150 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2022 | 1163 | 0.150 |
Why?
|
| Colon, Ascending | 1 | 2018 | 8 | 0.140 |
Why?
|
| Colon, Sigmoid | 1 | 2018 | 14 | 0.140 |
Why?
|
| Neomycin | 1 | 2018 | 37 | 0.140 |
Why?
|
| Citric Acid | 1 | 2018 | 38 | 0.140 |
Why?
|
| Cardiovascular Diseases | 2 | 2008 | 2093 | 0.140 |
Why?
|
| Episode of Care | 1 | 2017 | 3 | 0.140 |
Why?
|
| Adenocarcinoma | 3 | 2018 | 1070 | 0.140 |
Why?
|
| Prospective Studies | 7 | 2015 | 6617 | 0.140 |
Why?
|
| Organometallic Compounds | 1 | 2018 | 113 | 0.140 |
Why?
|
| Liver Neoplasms | 3 | 2018 | 1416 | 0.140 |
Why?
|
| Cognitive Dissonance | 1 | 2017 | 3 | 0.140 |
Why?
|
| Malnutrition | 1 | 2020 | 221 | 0.140 |
Why?
|
| Metronidazole | 1 | 2018 | 157 | 0.130 |
Why?
|
| Probability | 4 | 2004 | 334 | 0.130 |
Why?
|
| Cultural Characteristics | 1 | 2017 | 43 | 0.130 |
Why?
|
| Arthroplasty, Replacement | 1 | 2017 | 26 | 0.130 |
Why?
|
| Databases, Factual | 3 | 2018 | 1260 | 0.130 |
Why?
|
| Prognosis | 6 | 2014 | 5085 | 0.130 |
Why?
|
| Social Responsibility | 1 | 2017 | 83 | 0.130 |
Why?
|
| Statistics, Nonparametric | 3 | 2013 | 454 | 0.130 |
Why?
|
| Hepatectomy | 3 | 2014 | 124 | 0.130 |
Why?
|
| Sensitivity and Specificity | 3 | 2015 | 2171 | 0.130 |
Why?
|
| Personality | 1 | 2017 | 115 | 0.120 |
Why?
|
| Administration, Oral | 1 | 2018 | 725 | 0.120 |
Why?
|
| Coronary Artery Bypass | 1 | 2019 | 536 | 0.120 |
Why?
|
| Anesthesia, General | 2 | 2007 | 125 | 0.120 |
Why?
|
| Sex Factors | 2 | 2017 | 1388 | 0.120 |
Why?
|
| Sampling Studies | 2 | 2004 | 79 | 0.110 |
Why?
|
| Perineum | 1 | 2014 | 48 | 0.110 |
Why?
|
| Rectum | 3 | 2012 | 113 | 0.110 |
Why?
|
| Linezolid | 1 | 2014 | 27 | 0.110 |
Why?
|
| Morbidity | 1 | 2015 | 256 | 0.110 |
Why?
|
| Anal Canal | 1 | 2014 | 82 | 0.110 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1183 | 0.110 |
Why?
|
| Organ Sparing Treatments | 1 | 2014 | 45 | 0.110 |
Why?
|
| Liver Failure | 2 | 2005 | 91 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 1312 | 0.110 |
Why?
|
| CCAAT-Enhancer-Binding Protein-alpha | 2 | 2004 | 15 | 0.110 |
Why?
|
| Equipment Design | 3 | 2019 | 609 | 0.110 |
Why?
|
| Robotic Surgical Procedures | 1 | 2018 | 232 | 0.110 |
Why?
|
| Drug Therapy | 1 | 2014 | 94 | 0.110 |
Why?
|
| Odds Ratio | 2 | 2017 | 1338 | 0.100 |
Why?
|
| Immunocompromised Host | 1 | 2015 | 306 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 2 | 2015 | 1626 | 0.100 |
Why?
|
| Administration, Intravenous | 1 | 2014 | 162 | 0.100 |
Why?
|
| Cause of Death | 1 | 2015 | 506 | 0.100 |
Why?
|
| Abdominal Wound Closure Techniques | 1 | 2013 | 6 | 0.100 |
Why?
|
| Enterococcus | 1 | 2013 | 31 | 0.100 |
Why?
|
| Biomarkers | 2 | 2018 | 3434 | 0.100 |
Why?
|
| Staphylococcus epidermidis | 1 | 2013 | 40 | 0.100 |
Why?
|
| Age Factors | 4 | 2017 | 2997 | 0.100 |
Why?
|
| Polytetrafluoroethylene | 1 | 2013 | 75 | 0.100 |
Why?
|
| Fasciitis, Necrotizing | 2 | 2011 | 30 | 0.100 |
Why?
|
| Vascular Surgical Procedures | 1 | 2018 | 563 | 0.100 |
Why?
|
| Hand-Assisted Laparoscopy | 1 | 2012 | 3 | 0.100 |
Why?
|
| Neoplasm Staging | 4 | 2018 | 1391 | 0.100 |
Why?
|
| Colon | 3 | 2012 | 380 | 0.090 |
Why?
|
| Coronary Artery Disease | 1 | 2019 | 896 | 0.090 |
Why?
|
| Program Development | 2 | 2009 | 190 | 0.090 |
Why?
|
| Substance-Related Disorders | 1 | 2016 | 494 | 0.090 |
Why?
|
| Wound Closure Techniques | 1 | 2012 | 28 | 0.090 |
Why?
|
| Orchiopexy | 1 | 2011 | 2 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 867 | 0.090 |
Why?
|
| Robotics | 1 | 2013 | 110 | 0.090 |
Why?
|
| Carcinoma | 2 | 2005 | 321 | 0.090 |
Why?
|
| Long-Term Care | 1 | 2011 | 73 | 0.090 |
Why?
|
| Pain Measurement | 1 | 2013 | 369 | 0.090 |
Why?
|
| Education, Medical, Graduate | 2 | 2008 | 567 | 0.090 |
Why?
|
| Ambulatory Care | 1 | 2014 | 416 | 0.090 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2011 | 87 | 0.090 |
Why?
|
| Hospitals, University | 1 | 2011 | 107 | 0.090 |
Why?
|
| Cancer Care Facilities | 1 | 2011 | 40 | 0.090 |
Why?
|
| Personality Tests | 1 | 2010 | 17 | 0.090 |
Why?
|
| Chronic Pain | 1 | 2013 | 149 | 0.090 |
Why?
|
| Amiodarone | 1 | 2010 | 46 | 0.080 |
Why?
|
| Population Surveillance | 2 | 2011 | 419 | 0.080 |
Why?
|
| Abscess | 1 | 2011 | 140 | 0.080 |
Why?
|
| 2-Propanol | 1 | 2010 | 3 | 0.080 |
Why?
|
| Povidone-Iodine | 1 | 2010 | 10 | 0.080 |
Why?
|
| Double-Blind Method | 1 | 2014 | 1666 | 0.080 |
Why?
|
| Anxiety | 1 | 2016 | 1004 | 0.080 |
Why?
|
| Severity of Illness Index | 4 | 2011 | 3119 | 0.080 |
Why?
|
| Chlorhexidine | 1 | 2010 | 49 | 0.080 |
Why?
|
| Intestinal Fistula | 1 | 2009 | 29 | 0.080 |
Why?
|
| Education, Medical, Continuing | 1 | 2010 | 145 | 0.080 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2016 | 651 | 0.080 |
Why?
|
| Silver Sulfadiazine | 1 | 2009 | 9 | 0.080 |
Why?
|
| Academic Medical Centers | 2 | 2008 | 334 | 0.080 |
Why?
|
| Rectal Diseases | 1 | 2009 | 21 | 0.080 |
Why?
|
| Feasibility Studies | 1 | 2012 | 827 | 0.080 |
Why?
|
| Alcoholism | 1 | 2011 | 253 | 0.080 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2009 | 93 | 0.080 |
Why?
|
| Colonic Diseases | 1 | 2009 | 38 | 0.070 |
Why?
|
| Referral and Consultation | 2 | 2014 | 574 | 0.070 |
Why?
|
| Workload | 2 | 2008 | 151 | 0.070 |
Why?
|
| Respiration, Artificial | 1 | 2011 | 500 | 0.070 |
Why?
|
| Ischemia | 1 | 2011 | 386 | 0.070 |
Why?
|
| Surgery Department, Hospital | 1 | 2008 | 22 | 0.070 |
Why?
|
| Depression | 1 | 2016 | 1365 | 0.070 |
Why?
|
| Cooperative Behavior | 1 | 2008 | 233 | 0.070 |
Why?
|
| Chi-Square Distribution | 3 | 2017 | 606 | 0.070 |
Why?
|
| Intestines | 1 | 2011 | 614 | 0.070 |
Why?
|
| Patient Safety | 1 | 2012 | 436 | 0.070 |
Why?
|
| Competency-Based Education | 1 | 2008 | 79 | 0.070 |
Why?
|
| Hypercholesterolemia | 1 | 2009 | 236 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 1 | 2009 | 221 | 0.070 |
Why?
|
| Needlestick Injuries | 1 | 2006 | 6 | 0.070 |
Why?
|
| Blood-Borne Pathogens | 1 | 2006 | 6 | 0.070 |
Why?
|
| Cyclonic Storms | 1 | 2008 | 80 | 0.060 |
Why?
|
| Psychometrics | 1 | 2010 | 690 | 0.060 |
Why?
|
| Phosphates | 1 | 2007 | 121 | 0.060 |
Why?
|
| Survival Analysis | 3 | 2004 | 1595 | 0.060 |
Why?
|
| Debridement | 2 | 2005 | 92 | 0.060 |
Why?
|
| Inpatients | 1 | 2010 | 551 | 0.060 |
Why?
|
| Cross Circulation | 1 | 2005 | 4 | 0.060 |
Why?
|
| Hemoperfusion | 1 | 2005 | 5 | 0.060 |
Why?
|
| Liver, Artificial | 1 | 2005 | 9 | 0.060 |
Why?
|
| Dialysis | 1 | 2005 | 19 | 0.060 |
Why?
|
| Education, Nursing | 1 | 2005 | 17 | 0.060 |
Why?
|
| Rectus Abdominis | 1 | 2005 | 10 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2010 | 483 | 0.060 |
Why?
|
| Plasmapheresis | 1 | 2005 | 33 | 0.060 |
Why?
|
| Vancomycin | 1 | 2007 | 236 | 0.060 |
Why?
|
| Peritoneum | 1 | 2005 | 40 | 0.060 |
Why?
|
| Extracorporeal Circulation | 1 | 2005 | 55 | 0.060 |
Why?
|
| Occupational Exposure | 1 | 2006 | 139 | 0.060 |
Why?
|
| Polyethylene Glycols | 1 | 2007 | 257 | 0.060 |
Why?
|
| Albumins | 1 | 2005 | 99 | 0.060 |
Why?
|
| Primates | 1 | 2005 | 87 | 0.060 |
Why?
|
| Body Mass Index | 1 | 2011 | 1722 | 0.060 |
Why?
|
| Transplantation, Heterologous | 1 | 2005 | 276 | 0.060 |
Why?
|
| Immune Tolerance | 1 | 2005 | 153 | 0.060 |
Why?
|
| Serum Response Factor | 1 | 2004 | 31 | 0.060 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2004 | 41 | 0.060 |
Why?
|
| Teaching | 1 | 2006 | 200 | 0.060 |
Why?
|
| Hematoma | 1 | 2005 | 94 | 0.060 |
Why?
|
| Liver | 2 | 2003 | 1876 | 0.060 |
Why?
|
| Anesthesia, Local | 1 | 2004 | 40 | 0.060 |
Why?
|
| Liver Function Tests | 1 | 2004 | 106 | 0.060 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2007 | 836 | 0.060 |
Why?
|
| Perfusion | 1 | 2005 | 214 | 0.060 |
Why?
|
| Pelvis | 1 | 2004 | 74 | 0.060 |
Why?
|
| Cholecystectomy | 1 | 2004 | 64 | 0.060 |
Why?
|
| HIV | 1 | 2005 | 193 | 0.050 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2004 | 21 | 0.050 |
Why?
|
| Mitogens | 1 | 2004 | 32 | 0.050 |
Why?
|
| Health Status Indicators | 1 | 2004 | 130 | 0.050 |
Why?
|
| Anesthesiology | 1 | 2005 | 99 | 0.050 |
Why?
|
| Endarterectomy, Carotid | 1 | 2004 | 95 | 0.050 |
Why?
|
| Gallbladder | 1 | 2003 | 21 | 0.050 |
Why?
|
| Propensity Score | 1 | 2025 | 263 | 0.050 |
Why?
|
| Cholecystitis | 1 | 2003 | 21 | 0.050 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2018 | 1006 | 0.050 |
Why?
|
| Ascites | 1 | 2004 | 111 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2005 | 653 | 0.050 |
Why?
|
| Mass Screening | 1 | 2009 | 845 | 0.050 |
Why?
|
| Carotid Stenosis | 1 | 2004 | 135 | 0.050 |
Why?
|
| Blood Transfusion | 1 | 2005 | 296 | 0.050 |
Why?
|
| Liver Regeneration | 1 | 2003 | 41 | 0.050 |
Why?
|
| Hypercalcemia | 1 | 2003 | 42 | 0.050 |
Why?
|
| Terminology as Topic | 1 | 2004 | 235 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2009 | 681 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2004 | 212 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2004 | 298 | 0.050 |
Why?
|
| ROC Curve | 1 | 2004 | 614 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2003 | 204 | 0.050 |
Why?
|
| Prevalence | 1 | 2009 | 2685 | 0.050 |
Why?
|
| Acute Disease | 2 | 2003 | 1190 | 0.050 |
Why?
|
| Young Adult | 2 | 2014 | 9963 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2004 | 353 | 0.050 |
Why?
|
| Skin | 3 | 2013 | 545 | 0.050 |
Why?
|
| Norepinephrine | 1 | 2022 | 175 | 0.050 |
Why?
|
| Alternative Splicing | 1 | 2004 | 379 | 0.050 |
Why?
|
| Swine | 1 | 2005 | 1213 | 0.050 |
Why?
|
| Isoleucine | 1 | 2001 | 30 | 0.050 |
Why?
|
| Graft Rejection | 1 | 2005 | 568 | 0.050 |
Why?
|
| Lymph Node Excision | 2 | 2013 | 176 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2006 | 2204 | 0.050 |
Why?
|
| Blood Loss, Surgical | 2 | 2013 | 158 | 0.040 |
Why?
|
| Ammonia | 1 | 2001 | 77 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 2022 | 147 | 0.040 |
Why?
|
| Angiotensin II | 1 | 2022 | 173 | 0.040 |
Why?
|
| Tyrosine | 1 | 2001 | 157 | 0.040 |
Why?
|
| Valine | 1 | 2001 | 116 | 0.040 |
Why?
|
| Phenylalanine | 1 | 2001 | 134 | 0.040 |
Why?
|
| Bilirubin | 1 | 2001 | 131 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2004 | 682 | 0.040 |
Why?
|
| Hypertension | 1 | 2009 | 1409 | 0.040 |
Why?
|
| Blood Coagulation | 1 | 2001 | 134 | 0.040 |
Why?
|
| Adolescent | 2 | 2014 | 20647 | 0.040 |
Why?
|
| Hepatic Encephalopathy | 1 | 2001 | 94 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 625 | 0.040 |
Why?
|
| Leucine | 1 | 2001 | 312 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2002 | 745 | 0.040 |
Why?
|
| Medical Records | 2 | 2011 | 194 | 0.040 |
Why?
|
| Bipolar Disorder | 1 | 2003 | 367 | 0.040 |
Why?
|
| Lymphoma | 1 | 2002 | 334 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2005 | 893 | 0.040 |
Why?
|
| Nutritional Status | 1 | 2020 | 324 | 0.040 |
Why?
|
| Necrosis | 2 | 2011 | 220 | 0.040 |
Why?
|
| Cell Division | 3 | 2004 | 773 | 0.040 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2018 | 105 | 0.040 |
Why?
|
| Blue Cross Blue Shield Insurance Plans | 1 | 2017 | 2 | 0.030 |
Why?
|
| Administrative Claims, Healthcare | 1 | 2017 | 16 | 0.030 |
Why?
|
| Rehabilitation | 1 | 2017 | 23 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2011 | 1144 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2018 | 259 | 0.030 |
Why?
|
| Patient Care Bundles | 1 | 2017 | 26 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 308 | 0.030 |
Why?
|
| Bile Duct Neoplasms | 1 | 2018 | 121 | 0.030 |
Why?
|
| Cholangiocarcinoma | 1 | 2018 | 121 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2013 | 3678 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 1 | 2002 | 703 | 0.030 |
Why?
|
| Liver Transplantation | 1 | 2005 | 1122 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2017 | 187 | 0.030 |
Why?
|
| Aging | 1 | 2003 | 1308 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 723 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 1486 | 0.030 |
Why?
|
| Kidney | 1 | 2001 | 1404 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2004 | 4939 | 0.030 |
Why?
|
| SEER Program | 1 | 2014 | 224 | 0.030 |
Why?
|
| HIV Infections | 1 | 2005 | 2073 | 0.030 |
Why?
|
| Animals | 5 | 2005 | 36526 | 0.030 |
Why?
|
| Rats | 3 | 2004 | 3876 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2014 | 247 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2014 | 457 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2013 | 406 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2011 | 339 | 0.020 |
Why?
|
| Antisepsis | 1 | 2010 | 8 | 0.020 |
Why?
|
| Personnel Selection | 1 | 2011 | 67 | 0.020 |
Why?
|
| Contraindications | 1 | 2009 | 77 | 0.020 |
Why?
|
| Dissection | 1 | 2009 | 58 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2011 | 465 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2010 | 284 | 0.020 |
Why?
|
| Anastomosis, Surgical | 1 | 2009 | 165 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 972 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2009 | 135 | 0.020 |
Why?
|
| Utilization Review | 1 | 2008 | 41 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 563 | 0.020 |
Why?
|
| Models, Psychological | 1 | 2008 | 145 | 0.020 |
Why?
|
| Accreditation | 1 | 2008 | 94 | 0.020 |
Why?
|
| Models, Educational | 1 | 2008 | 75 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2007 | 77 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2011 | 520 | 0.020 |
Why?
|
| Efficiency | 1 | 2008 | 70 | 0.020 |
Why?
|
| Cefotetan | 1 | 2007 | 1 | 0.020 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2008 | 83 | 0.020 |
Why?
|
| Hernia, Femoral | 1 | 2006 | 1 | 0.020 |
Why?
|
| Operating Room Nursing | 1 | 2006 | 1 | 0.020 |
Why?
|
| beta-Lactams | 1 | 2007 | 56 | 0.020 |
Why?
|
| Colonoscopy | 1 | 2009 | 249 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2006 | 115 | 0.020 |
Why?
|
| Sutures | 1 | 2006 | 68 | 0.020 |
Why?
|
| Problem-Based Learning | 1 | 2006 | 73 | 0.020 |
Why?
|
| HIV Antibodies | 1 | 2005 | 71 | 0.010 |
Why?
|
| Compartment Syndromes | 1 | 2005 | 32 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2005 | 239 | 0.010 |
Why?
|
| Lumbosacral Region | 1 | 2004 | 25 | 0.010 |
Why?
|
| Ilium | 1 | 2004 | 22 | 0.010 |
Why?
|
| Rupture, Spontaneous | 1 | 2004 | 50 | 0.010 |
Why?
|
| 3T3-L1 Cells | 1 | 2004 | 58 | 0.010 |
Why?
|
| Purinergic P2 Receptor Antagonists | 1 | 2004 | 5 | 0.010 |
Why?
|
| Bone Transplantation | 1 | 2004 | 52 | 0.010 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2004 | 17 | 0.010 |
Why?
|
| Receptors, Purinergic P2Y2 | 1 | 2004 | 16 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2004 | 40 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 1317 | 0.010 |
Why?
|
| Protein C | 1 | 2004 | 21 | 0.010 |
Why?
|
| Extracellular Space | 1 | 2004 | 89 | 0.010 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2004 | 39 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2004 | 331 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2004 | 60 | 0.010 |
Why?
|
| Partial Thromboplastin Time | 1 | 2004 | 50 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2004 | 93 | 0.010 |
Why?
|
| Cyclin D1 | 1 | 2004 | 123 | 0.010 |
Why?
|
| Transcription Factor AP-1 | 1 | 2004 | 112 | 0.010 |
Why?
|
| Age Distribution | 1 | 2004 | 445 | 0.010 |
Why?
|
| Genes, Regulator | 1 | 2003 | 57 | 0.010 |
Why?
|
| E2F4 Transcription Factor | 1 | 2003 | 10 | 0.010 |
Why?
|
| Transcription Factors | 2 | 2004 | 2735 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 2003 | 107 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2005 | 563 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2003 | 252 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 2003 | 186 | 0.010 |
Why?
|
| Genes, myc | 1 | 2003 | 107 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 2003 | 86 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2003 | 388 | 0.010 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2003 | 90 | 0.010 |
Why?
|
| Interleukins | 1 | 2004 | 130 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2004 | 260 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 738 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2004 | 1109 | 0.010 |
Why?
|
| Emergency Medical Services | 1 | 2006 | 415 | 0.010 |
Why?
|
| Cell Survival | 1 | 2004 | 890 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2007 | 1222 | 0.010 |
Why?
|
| Biopsy | 1 | 2005 | 1303 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2004 | 514 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2004 | 645 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2004 | 471 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 1436 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2004 | 1715 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2003 | 1434 | 0.010 |
Why?
|
| Quality of Life | 1 | 2009 | 2163 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2003 | 1051 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2003 | 874 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 3181 | 0.010 |
Why?
|
| Apoptosis | 1 | 2004 | 1945 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2004 | 3800 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2003 | 938 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 2178 | 0.010 |
Why?
|
| Mutation | 1 | 2004 | 6350 | 0.010 |
Why?
|
| Mice | 1 | 2004 | 19049 | 0.000 |
Why?
|